◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Hansoh Pharmaceutical Group Company Limited (3692)

Name: Hansoh Pharmaceutical Group Company Limited（3692）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-09-30

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases.

主要指標

時価総額: HK$214 billion
売上高（2025-12-31 期末の会計年度）: CNY 15.0B
当期純利益: CNY 5.6B
売上総利益率: 90.0%
純利益率: 37.0%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	2025-12-31	2024-12-31	2023-12-31	2022-12-31
売上高合計	CNY 15.0B	CNY 12.3B	CNY 10.1B	CNY 9.4B
売上総利益	CNY 13.5B	CNY 11.2B	CNY 9.1B	CNY 8.5B
営業利益（EBIT）	CNY 5.5B	CNY 4.0B	CNY 2.8B	CNY 2.8B
当期純利益	CNY 5.6B	CNY 4.4B	CNY 3.3B	CNY 2.6B

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は 3692 のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/3692

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.